Peptides
Kalpa Pharmaceuticals
Tesamorelin 5 mg
Product Information Compound Details
Active Substance Tesamorelin Growth hormone-releasing hormone analogue
5 mg/vialStrength 5 mg/vial
Package 2 mL Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class GHRH Analogue
Manufacturer Kalpa Pharmaceuticals
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
Tesamorelin 5 mg by Kalpa Pharmaceuticals
Tesamorelin 5 mg is a lyophilized growth hormone-releasing hormone analogue formulation manufactured by Kalpa Pharmaceuticals and supplied in a 2 mL vial at 5 mg/vial.
Growth Hormone-Releasing Hormone Analogue
Tesamorelin 5 mg contains tesamorelin, a synthetic analogue of human growth hormone-releasing hormone (GHRH), also known as growth hormone-releasing factor (GRF). Tesamorelin binds and stimulates human GHRF receptors with similar potency as endogenous GRF, acting on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone. GH is both anabolic and lipolytic, exerting effects by interacting with specific receptors on target cells including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes.
Tesamorelin is an FDA-approved human pharmaceutical product marketed as EGRIFTA WR and EGRIFTA SV by Theratechnologies. It is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Notably, EGRIFTA WR is not indicated for weight loss management as it has a weight-neutral effect. The FDA-approved dosage for EGRIFTA WR is 1.28 mg subcutaneously once daily.
In research and non-medical contexts, tesamorelin is commonly referenced for its effects on visceral adipose tissue and growth hormone secretion. When used outside approved indications, the potential for adverse effects exists and such use falls outside approved medical indications.
Key Benefits of Tesamorelin 5 mg
- GHRH analogue that stimulates endogenous growth hormone release
- Lyophilized powder for stability and reconstitution flexibility
- FDA-approved for reduction of excess abdominal fat in HIV lipodystrophy
- Demonstrated significant reductions in visceral adipose tissue in clinical trials
- No clinically significant changes in other pituitary hormones observed in trials
Formulation
Lyophilized Powder
Tesamorelin 5 mg is supplied as a lyophilized powder that requires reconstitution with an appropriate diluent such as Bacteriostatic Water before use. This formulation is designed to preserve the stability of the peptide until it is ready for use.
Product Profile
Tesamorelin Profile
Tesamorelin is a synthetic GHRH analogue with an established clinical profile. Its mechanism of action and physiological effects distinguish it from anabolic steroids and other performance compounds.
GHRH Analogue Mechanism
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), a hypothalamic peptide that acts on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone. In vitro, tesamorelin binds and stimulates human GHRF receptors with similar potency as endogenous GRF.
Tesamorelin stimulates growth hormone secretion, subsequently increasing IGF-1 and IGFBP-3 levels. In Phase 3 clinical trials, no clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in subjects receiving EGRIFTA.
The absolute bioavailability of tesamorelin after subcutaneous administration is less than 4% in healthy adult subjects. The mean elimination half-life is 26 minutes in healthy subjects and 38 minutes in HIV-infected patients.
Clinical Profile
FDA-Approved for HIV Lipodystrophy
Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. In clinical trials, EGRIFTA-treated patients demonstrated significant reductions in visceral adipose tissue compared with placebo.
Tesamorelin 5 mg vs Other Kalpa Preparations
Kalpa Pharmaceuticals offers several peptide and research formulations. The main practical distinction between these preparations involves the compound's mechanism and intended research or educational context.
Unlike anabolic steroids such as Testoxyl Cypionate 250 or Trenboxyl Acetate, tesamorelin is not an androgen and works through GHRH receptor pathways rather than androgen receptor activation. For other growth hormone-related options in the Kalpa catalog, Ipamorelin 5 mg is a ghrelin receptor agonist that stimulates GH release through a different mechanism, Kalpatropin HGH provides exogenous somatropin, and MOTS-c 10 mg is a mitochondrial-derived peptide studied for metabolic regulation.
Dosage & Usage
Tesamorelin 5 mg Dosage & Usage
The information below is provided for educational and research reference only. Tesamorelin is an FDA-approved human pharmaceutical product in specific formulations. This product is a research-grade lyophilized powder and is not an FDA-approved formulation. Non-medical use falls outside approved indications.
Typical Research Reference Ranges
In FDA-approved formulations, the recommended dosage of EGRIFTA WR is 1.28 mg subcutaneously once daily, injected into the abdomen with rotation of injection sites. For EGRIFTA SV (2 mg/vial formulation), the dose is 1.4 mg injected subcutaneously once daily. These ranges are derived from FDA-approved product labeling and are provided for educational reference only.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| EGRIFTA WR (FDA-approved) | 1.28 mg | Once daily subcutaneous |
| EGRIFTA SV (FDA-approved) | 1.4 mg | Once daily subcutaneous |
| Research reference range | 1–2 mg | Once daily subcutaneous |
Reconstitution & Handling Considerations
Tesamorelin 5 mg is supplied as a lyophilized powder that requires reconstitution with an appropriate diluent such as Bacteriostatic Water before use. The FDA-approved EGRIFTA WR formulation uses Bacteriostatic Water for Injection as the diluent, with 1 vial reconstituted with 1.3 mL of diluent (8 mg per mL).
Reconstitution should involve adding the diluent slowly down the side of the vial rather than directly onto the powder, followed by gentle swirling or rolling rather than shaking. Once reconstituted, the solution should be inspected for particulate matter and discoloration prior to administration. EGRIFTA WR is a clear, colorless solution; do not use if solid particles appear or if the solution is cloudy or colored.
Managing Side Effects
The most common side effects of EGRIFTA WR include pain in legs and arms and muscle pain. Serious side effects include increased risk of new cancer in HIV-positive patients or cancer reactivation, increased IGF-1 levels, fluid retention (swelling, joint pain, carpal tunnel syndrome), increase in blood sugar or diabetes, serious allergic reactions, and injection site reactions.
EGRIFTA WR treatment can result in glucose intolerance. During clinical trials, the percentages of patients with elevated HbA1c (≥ 6.5%) from baseline to Week 26 were 5% and 1% in the EGRIFTA and placebo groups, respectively. Aromatase inhibitors such as Arimixyl are not relevant to tesamorelin use as it does not affect the aromatase pathway.
Post-Research Considerations
Post-cycle therapy is not applicable to tesamorelin, as it is not a compound that suppresses the hypothalamic-pituitary-gonadal axis. It is a GHRH analogue studied for reduction of visceral adipose tissue. When tesamorelin is used as part of a broader research protocol that includes anabolic compounds, standard PCT protocols such as those involving Clomixyl or Nolvaxyl would be relevant to those compounds, not to tesamorelin itself.
Important
Individual Response Varies
Research protocols, reconstitution procedures and handling practices should be adjusted based on the specific context and the guidelines provided with the product. The information above is for educational reference and does not constitute medical advice.
Safety & Information
Tesamorelin Safety Information
Tesamorelin is an FDA-approved human pharmaceutical product with well-characterized safety information. It can affect hormonal, metabolic, and neoplastic risk profiles. Medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Important Safety Information
EGRIFTA WR is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma, active malignancy, known hypersensitivity to tesamorelin or excipients, and in pregnant women.
EGRIFTA WR induces the release of endogenous growth hormone (GH), a known growth factor. Do not treat patients with active malignancy with EGRIFTA WR. Carefully consider the decision to start treatment based on the increased background risk of malignancies in HIV-positive patients.
Important
Increased Risk of Neoplasms
EGRIFTA WR carries a warning regarding increased risk of neoplasms. For patients with a history of non-malignant neoplasms, initiate therapy after careful evaluation of the potential benefit of treatment. For patients with a history of treated and stable malignancies, initiate therapy only after careful evaluation of the potential benefit relative to the risk of re-activation of the underlying malignancy.
Potential Adverse Effects
EGRIFTA WR can cause serious side effects including increased risk of new cancer in HIV-positive patients or cancer reactivation, increased levels of IGF-1 (requiring blood test monitoring), fluid retention (swelling, joint pain, carpal tunnel syndrome), increase in blood sugar or diabetes, serious allergic reactions, and injection site reactions.
Among patients who received EGRIFTA for 26 weeks, 47% had IGF-1 levels greater than 2 standard deviation scores (SDS), and 36% had SDS >3, with this effect seen as early as 13 weeks of treatment. Consider discontinuing EGRIFTA in patients with persistent elevations of IGF-1 levels (e.g., >3 SDS), particularly if the efficacy response is not robust.
EGRIFTA treatment can result in glucose intolerance. During clinical trials, the percentages of patients with elevated HbA1c (≥ 6.5%) from baseline to Week 26 were 5% and 1% in the EGRIFTA and placebo groups, respectively. An increased risk of developing diabetes with EGRIFTA (HbA1c level ≥ 6.5%) relative to placebo was observed.
Conditions Requiring Medical Evaluation
Patients with a history of cancer should be carefully evaluated before initiating therapy. EGRIFTA SV is not for use in patients with active cancer, and any previous cancer should be inactive and treatment complete before starting therapy. Patients with diabetes or problems with blood sugar should be monitored, as some people with diabetes who use EGRIFTA SV may develop or experience worsening eye problems.
Pregnant women should not use tesamorelin because modifying visceral adipose tissue offers no benefit in pregnancy and could result in fetal harm.
Monitoring Considerations
Medically supervised tesamorelin therapy typically involves follow-up assessment to evaluate treatment response, adverse effects and relevant laboratory markers. Monitoring includes IGF-1 levels during therapy, blood sugar before and during treatment, and periodic evaluation for potential adverse effects.
For non-medical use of Tesamorelin 5 mg, such monitoring is not typically performed, which increases the risk of unrecognized adverse effects.
Product Care
Storage & Handling
Lyophilized tesamorelin powder should be stored under refrigeration according to the manufacturer's instructions. Reconstituted solution should be stored at room temperature at 20°C to 25°C (68°F to 77°F) and used within the recommended timeframe. Do not freeze the reconstituted solution.
Keep all medications and research products out of the reach of children. Follow the storage instructions provided with the product packaging.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Tesamorelin 5 mg is supplied through the official Kalpa Pharmaceuticals distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Kalpa Pharmaceuticals distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Tesamorelin 5 mg product, use the security code on the vial label and cross-check it on the Kalpa official site. Official Kalpa Pharmaceuticals presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Tesamorelin 5 mg Storage
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Recommended Conditions
Lyophilized tesamorelin powder should be stored under refrigeration according to the manufacturer's instructions. Protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the peptide formulation.
After reconstitution, EGRIFTA WR should be stored at room temperature at 20°C to 25°C (68°F to 77°F). One reconstituted EGRIFTA WR vial provides daily doses for 7 consecutive days. Do not freeze the reconstituted solution. Before each use, inspect the solution and avoid use if it appears cloudy, discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile practices when using the product.
Quick Reference
Do & Don't
- Do store lyophilized powder under refrigeration
- Do keep in original packaging
- Do inspect before each use
- Don't freeze reconstituted solution
- Don't expose to direct sunlight
- Don't use if solution looks abnormal
Frequently Asked Questions
Tesamorelin 5 mg FAQ
Answers to common questions about Tesamorelin 5 mg, the GHRH analogue, and its research and safety profile.
What does taking tesamorelin do?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that binds and stimulates human GHRF receptors with similar potency as endogenous GRF. It acts on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone.
GH is both anabolic and lipolytic, and tesamorelin has been shown to reduce excess abdominal fat in HIV-infected patients with lipodystrophy in clinical trials.
Is tesamorelin the same as Ozempic?
No, tesamorelin and Ozempic (semaglutide) are different compounds with different mechanisms of action. Tesamorelin is a GHRH analogue that stimulates endogenous growth hormone release. Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion and increases satiety.
Tesamorelin is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, while semaglutide is approved for type 2 diabetes and chronic weight management.
Will tesamorelin get rid of belly fat?
Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. In clinical trials, EGRIFTA-treated patients demonstrated significant reductions in visceral adipose tissue compared with placebo.
However, EGRIFTA WR is not indicated for weight loss management as it has a weight-neutral effect. Its effect is specific to visceral adipose tissue reduction, not general weight loss.
Who should not take tesamorelin?
Tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma, active malignancy, known hypersensitivity to tesamorelin or excipients, and in pregnant women.
Patients with a history of cancer should be carefully evaluated, as EGRIFTA WR carries a warning regarding increased risk of neoplasms.
What is Tesamorelin 5 mg used for?
Tesamorelin 5 mg contains the GHRH analogue tesamorelin in lyophilized powder form. It is supplied for research and educational purposes. In clinical practice, tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
This research-grade formulation is not an FDA-approved product and is not intended for human use outside approved research contexts.
How often should Tesamorelin 5 mg be used?
In FDA-approved formulations, the recommended dosage of EGRIFTA WR is 1.28 mg subcutaneously once daily, injected into the abdomen with rotation of injection sites. The half-life of tesamorelin is 26–38 minutes depending on the population.
Dosing in research contexts should follow the protocols established in clinical trials. These frequencies are for educational reference only.
Does Tesamorelin 5 mg require PCT?
Post-cycle therapy is not applicable to tesamorelin, as it is not a compound that suppresses the hypothalamic-pituitary-gonadal axis. It is a GHRH analogue studied for reduction of visceral adipose tissue.
When tesamorelin is used as part of a broader research protocol that includes anabolic compounds, standard PCT protocols such as those involving Clomixyl or Nolvaxyl would be relevant to those compounds, not to tesamorelin itself.
What does tesamorelin do?
Tesamorelin binds and stimulates human GHRF receptors, acting on pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone. It subsequently increases IGF-1 and IGFBP-3 levels.
In clinical trials, no clinically significant changes in the levels of other pituitary hormones, including TSH, LH, ACTH and prolactin, were observed.
How long does tesamorelin take to work?
In clinical trials, the primary efficacy assessment was the percent change from baseline to Week 26 in visceral adipose tissue, as assessed by computed tomography scan. Significant reductions were observed at 26 weeks.
The time required to observe effects depends on the specific outcome being evaluated and individual factors. In clinical trials, effects on IGF-1 levels were seen as early as 13 weeks of treatment.
Is tesamorelin the best fat reduction drug?
Tesamorelin is FDA-approved specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a specific clinical population. It is not indicated for weight loss management as it has a weight-neutral effect.
Other therapies, such as GLP-1 receptor agonists, have broader weight loss indications. The appropriate choice depends on clinical circumstances and provider guidance.
What is the difference between Tesamorelin 5 mg and Ipamorelin 5 mg?
Tesamorelin 5 mg contains the GHRH analogue tesamorelin, which directly stimulates pituitary GH release through GHRH receptors. Ipamorelin 5 mg is a ghrelin receptor agonist that stimulates GH release through a different mechanism with minimal effects on cortisol and prolactin.
These are different compounds with different mechanisms and clinical profiles.
Is 5 mg of Tesamorelin a lot?
The milligram strength of the vial (5 mg) refers to the total amount of tesamorelin in the vial, not the amount administered per dose. In FDA-approved formulations, the recommended dosage of EGRIFTA WR is 1.28 mg once daily.
It is important to distinguish vial strength from administered dose. A 5 mg vial can be reconstituted with an appropriate volume of diluent to achieve the desired concentration for research or educational purposes.
Related Offers
Kalpa Pharmaceuticals LTD, India
Product Information Compound Details
Active Substance BPC-157 Pentadecapeptide (Body Protection Compound 157)
5 mg/vialStrength 5 mg/vial
Package 2 mL Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Kalpa Pharmaceuticals
Kalpa Pharmaceuticals LTD, India
Product Information Compound Details
Active Substance Ipamorelin Selective growth hormone secretagogue pentapeptide
5 mg/vialStrength 5 mg/vial
Package 2 mL Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Growth Hormone Secretagogue
Manufacturer Kalpa Pharmaceuticals
Kalpa Pharmaceuticals LTD, India
Product Information Compound Details
Active Substance MOTS-c Mitochondrial-derived peptide (16 amino acids)
5 mg/vialStrength 5 mg/vial
Package 2 mL Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Mitochondrial-Derived Peptide
Manufacturer Kalpa Pharmaceuticals
Kalpa Pharmaceuticals LTD, India
Product Information Compound Details
Active Substance GHK-Cu Copper Tripeptide-1 (Glycyl-L-histidyl-L-lysine copper complex)
50 mg/vialStrength 50 mg/vial
Package 2 mL Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Copper Peptide
Manufacturer Kalpa Pharmaceuticals